loading

Vyne Therapeutics Inc Aktie (VYNE) Neueste Nachrichten

pulisher
Apr 25, 2025

VYNE stock touches 52-week low at $1.38 amid market challenges - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

After A -27.64% Drop In Share Price, Is VYNE Therapeutics Inc (NASDAQ:VYNE) A Better Trade Than Others? - Marketing Sentinel

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics Inc (VYNE) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics Provides Update on VYN202 Program | VYNE Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE’s earnings forecast for the current quarter - uspostnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down. - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis - Dermatology Times

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics (VYNE) Target Price Cut Following FDA Clinical - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics (VYNE) Faces FDA Clinical Hold on Psoriasis Dr - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

With 36.89% Distance From Low, Could Vs Media Holdings Ltd (NASDAQ:VSME) Post Further Gains? - Marketing Sentinel

Apr 25, 2025
pulisher
Apr 25, 2025

Pre-market Movers: OMEX, SES, VYNE, OLB, LEXX… - RTTNews

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics Provides Update on VYN202 Program - The Manila Times

Apr 25, 2025
pulisher
Apr 24, 2025

VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 1.1% – Here’s What Happened - Defense World

Apr 24, 2025
pulisher
Apr 18, 2025

Is VYNE Therapeutics Inc (NASDAQ: VYNE) A Suitable Stock For New Investors Today? - Stocksregister

Apr 18, 2025
pulisher
Apr 08, 2025

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - Yahoo Finance

Apr 08, 2025
pulisher
Apr 04, 2025

Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail

Apr 04, 2025
pulisher
Apr 02, 2025

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World

Apr 02, 2025
pulisher
Mar 21, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Invesco Canada announces cash distributions for its ETFs - The Globe and Mail

Mar 21, 2025
pulisher
Mar 20, 2025

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

VYNE Therapeutics Showcases Breakthrough Autoimmune Disease Treatments at Major Conference - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

New Research Confirms Effective Therapy for Nail Psoriasis - Dermatology Times

Mar 20, 2025
pulisher
Mar 11, 2025

Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 11, 2025
pulisher
Mar 08, 2025

VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Inc. (VYNE) reports earnings - Quartz

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Vyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times

Mar 06, 2025
pulisher
Feb 27, 2025

VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 21, 2025

HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

VYNE Therapeutics to Participate in March Investor Conferences - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

Can VYNE Therapeutics' March Investor Conferences Reveal New Strategic Directions? - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details - StockTitan

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE begins trial for new psoriasis treatment - Investing.com

Feb 19, 2025
pulisher
Jan 20, 2025

VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World

Jan 20, 2025
pulisher
Jan 17, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia

Jan 17, 2025
pulisher
Jan 17, 2025

Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus

Jan 17, 2025
pulisher
Jan 14, 2025

VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail

Jan 13, 2025
pulisher
Jan 10, 2025

Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Jan 10, 2025
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):